Spots Global Cancer Trial Database for adenocarcinoma of the extrahepatic bile duct
Every month we try and update this database with for adenocarcinoma of the extrahepatic bile duct cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer | NCT00073905 | Extrahepatic Bi... Gallbladder Can... Liver Cancer Pain | capecitabine pl... | 18 Years - 80 Years | Swiss Group for Clinical Cancer Research | |
| Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder | NCT00085410 | Adenocarcinoma ... Adenocarcinoma ... Advanced Adult ... Gastrointestina... Localized Unres... Recurrent Adult... Recurrent Extra... Recurrent Gallb... Unresectable Ex... Unresectable Ga... | bortezomib | 18 Years - | National Cancer Institute (NCI) | |
| S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma | NCT00033540 | Extrahepatic Bi... Gallbladder Can... | capecitabine gemcitabine hyd... | 18 Years - | SWOG Cancer Research Network | |
| S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma | NCT00033540 | Extrahepatic Bi... Gallbladder Can... | capecitabine gemcitabine hyd... | 18 Years - | SWOG Cancer Research Network | |
| Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract Cancer | NCT00266097 | Extrahepatic Bi... Gallbladder Can... Pancreatic Canc... | erlotinib hydro... gemcitabine hyd... oxaliplatin radiation thera... gemcitabine hyd... Oxaliplatin | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Gemcitabine and Radiation Therapy in Treating Patients With Locally Advanced Upper Gastrointestinal Cancer | NCT00544193 | Extrahepatic Bi... Gallbladder Can... Gastric Cancer Pancreatic Canc... Small Intestine... | gemcitabine hyd... polymerase chai... immunohistochem... conventional su... intraoperative ... radiation thera... | 18 Years - 70 Years | City of Hope Medical Center | |
| Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract | NCT00012246 | Colorectal Canc... Esophageal Canc... Extrahepatic Bi... Gallbladder Can... Gastric Cancer Pancreatic Canc... Small Intestine... | carcinoembryoni... incomplete Freu... sargramostim | 18 Years - | The University of Texas Medical Branch, Galveston | |
| Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract Cancer | NCT00266097 | Extrahepatic Bi... Gallbladder Can... Pancreatic Canc... | erlotinib hydro... gemcitabine hyd... oxaliplatin radiation thera... gemcitabine hyd... Oxaliplatin | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery | NCT00478140 | Adenocarcinoma ... Adenocarcinoma ... Malignant Neopl... Recurrent Extra... Recurrent Gallb... Unresectable Ex... Unresectable Ga... | trastuzumab laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract | NCT00012246 | Colorectal Canc... Esophageal Canc... Extrahepatic Bi... Gallbladder Can... Gastric Cancer Pancreatic Canc... Small Intestine... | carcinoembryoni... incomplete Freu... sargramostim | 18 Years - | The University of Texas Medical Branch, Galveston | |
| RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma | NCT00101972 | Cancer | monoclonal anti... | 18 Years - | MacroGenics | |
| Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer | NCT00073905 | Extrahepatic Bi... Gallbladder Can... Liver Cancer Pain | capecitabine pl... | 18 Years - 80 Years | Swiss Group for Clinical Cancer Research | |
| Gemcitabine With/Out Capecitabine in Locally Advanced, Unresectable, or Metastatic Biliary Cancer | NCT00658593 | Extrahepatic Bi... Gallbladder Can... Liver Cancer | capecitabine gemcitabine hyd... quality-of-life... | 18 Years - 120 Years | Canadian Cancer Trials Group | |
| Gemcitabine With/Out Capecitabine in Locally Advanced, Unresectable, or Metastatic Biliary Cancer | NCT00658593 | Extrahepatic Bi... Gallbladder Can... Liver Cancer | capecitabine gemcitabine hyd... quality-of-life... | 18 Years - 120 Years | Canadian Cancer Trials Group | |
| Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery | NCT01313377 | Extrahepatic Bi... Gallbladder Can... Liver Cancer | gemcitabine hyd... oxaliplatin clinical observ... adjuvant therap... quality-of-life... | 18 Years - 120 Years | UNICANCER | |
| S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma | NCT00033540 | Extrahepatic Bi... Gallbladder Can... | capecitabine gemcitabine hyd... | 18 Years - | SWOG Cancer Research Network | |
| Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer | NCT00987766 | Extrahepatic Bi... Gallbladder Can... Liver Cancer Pancreatic Canc... Periampullary A... Small Intestine... | erlotinib hydro... gemcitabine hyd... oxaliplatin laboratory biom... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Gene Therapy in Treating Patients With Cancer | NCT00004178 | Cancer | therapeutic aut... | 18 Years - | Roger Williams Medical Center | |
| Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas or Bile Duct | NCT00010088 | Extrahepatic Bi... Pancreatic Canc... | fluorouracil gemcitabine hyd... leucovorin calc... conventional su... radiation thera... | 18 Years - 75 Years | National Cancer Institute (NCI) | |
| Gemcitabine and Radiation Therapy in Treating Patients With Locally Advanced Upper Gastrointestinal Cancer | NCT00544193 | Extrahepatic Bi... Gallbladder Can... Gastric Cancer Pancreatic Canc... Small Intestine... | gemcitabine hyd... polymerase chai... immunohistochem... conventional su... intraoperative ... radiation thera... | 18 Years - 70 Years | City of Hope Medical Center | |
| Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder | NCT00085410 | Adenocarcinoma ... Adenocarcinoma ... Advanced Adult ... Gastrointestina... Localized Unres... Recurrent Adult... Recurrent Extra... Recurrent Gallb... Unresectable Ex... Unresectable Ga... | bortezomib | 18 Years - | National Cancer Institute (NCI) | |
| Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery | NCT01313377 | Extrahepatic Bi... Gallbladder Can... Liver Cancer | gemcitabine hyd... oxaliplatin clinical observ... adjuvant therap... quality-of-life... | 18 Years - 120 Years | UNICANCER | |
| Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer | NCT00096083 | Cancer | isolated perfus... melphalan | 16 Years - | Delcath Systems Inc. | |
| Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery | NCT00478140 | Adenocarcinoma ... Adenocarcinoma ... Malignant Neopl... Recurrent Extra... Recurrent Gallb... Unresectable Ex... Unresectable Ga... | trastuzumab laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma | NCT00101972 | Cancer | monoclonal anti... | 18 Years - | MacroGenics |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
